Abrégé

The invention relates to an attenuated variant of the Rift Valley fever virus (RVFV) with mutations in the amino acid sequence coded by segments L, M, and S of RVFV RNA; a pharmaceutical or veterinary composition comprising same; an attenuated RVFV variant for use in the prevention of Rift Valley fever; and a vaccine against Rift Valley fever comprising the attenuated RVFV variant. Attenuated RVFV variants with the mutations Gly924Ser and Alal303Thr in protein L, and the Pro82Leu substitution in protein NSs, are also included.

Classes IPC  ?

• C12N 7/04 - Inactivation ou atténuationProduction de parties élémentaires de virus
• C12N 7/06 - Inactivation ou atténuationProduction de parties élémentaires de virus par traitement chimique
• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to a process for the treatment of beeswax from beekeeping farms, contaminated with residues of veterinary and phytosanitary treatments by means of a process of extraction of the molten wax with methanol and the subsequent steps for the adaptation of the wax obtained to manufacture hives therefrom that are accepted by the bees, and that can also be used in galenic formulations. Therefore, the technological framework in which this invention is included is that of beekeeping and, more specifically, beeswax extraction processes and devices.

Classes IPC  ?

• C11B 11/00 - Obtention ou raffinage d'autres matières grasses, p. ex. lanoline ou cires
• C08L 91/06 - Cires
• B01D 11/02 - Extraction par solvants de solides

Abrégé

The present invention relates to to sulfated phenylhydrazide derivatives of formula (I) as antiviral agents. Said compounds are therefore useful for the prevention and/or treatment of viral diseases such as the disease caused by Ebola virus, swine fever or coronavirus.

Classes IPC  ?

• C07C 243/28 - Hydrazines ayant des atomes d'azote de groupes hydrazine acylés par des acides carboxyliques avec des groupes carboxyle acylants liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes d'hydrogène ou à des atomes de carbone d'un squelette carboné saturé
• A61K 31/15 - Oximes (C=N-O-)Hydrazines ( N-N)Hydrazones (N-N=)
• A61P 31/12 - Antiviraux

Abrégé

The present invention relates to a plasmid that encodes a fusion protein comprising a signal peptide and the extracellular domain of B-cell activating factor receptor (BAFF-R), and optionally, a fragment of the constant region (Fe) of an immunoglobulin. The invention also relates to compositions comprising the plasmid, and to the use of same in the treatment and/or prevention of inflammatory diseases in fish, preferably in salmonids.

Classes IPC  ?

• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C07K 14/525 - Facteur de nécrose de tumeurs [TNF]
• A61K 38/19 - CytokinesLymphokinesInterférons

Abrégé

The invention relates to a device for selecting spermatozoa, which comprises: a selection unit (1) comprising a loading compartment (1b) and a recovery compartment (2b); a capillary section (3) that interconnects the loading compartment (1b) with the recovery compartment (2b); an exterior recipient (5) designed to engage a fastening unit (4) with the selection unit (1); heaters at each end of the selection unit (1); and a blocking unit (4c) in the capillary section (3), wherein the heaters at each end of the selection unit (1) generate a temperature gradient allowing the spermatozoa to migrate from the loading compartment (1b) to the recovery compartment (2b) for a determined amount of time until the blocking unit is actuated (4c), thereby selecting the spermatozoa with greater migratory capacity.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• B01L 7/00 - Appareils de chauffage ou de refroidissementDispositifs d'isolation thermique
• B01L 7/02 - Bains d'eauBains de sableBains d'air
• C12Q 1/24 - Méthodes d'échantillonnage, d'inoculation ou de développement d'un échantillonMéthodes pour isoler physiquement un micro-organisme intact
• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres

Abrégé

Sus scrofaSus scrofain vitroin vitro growth characteristics of the vaccine isolate Lv17/WB/Rie1 have been evaluated by culturing same in primary porcine peripheral blood monocyte (PBM) cultures obtained from the peripheral blood of domestic pigs. After a first pass of the vaccine virus in cell culture, the virus was collected to create a stock of Lv17/WB/Rie vaccine virus.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• C12N 7/04 - Inactivation ou atténuationProduction de parties élémentaires de virus
• A61P 31/20 - Antiviraux pour le traitement des virus ADN

Abrégé

The present invention provides an expression cassette comprising at least one polynucleotide comprising a nucleotide sequence selected from the group consisting of: a) a nucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NOs. 13-24; and b) a nucleic acid sequence that encodes a polypeptide having the amino acid sequence sharing at least 50%, preferably at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, especially preferably at least 90%, 95%, 97%, 98%, 99%, or more of sequence identity with a sequence selected in the group consisting of SEQ ID NOs. 13-24. This expression cassette can be used in vivo to increase in plants the tolerance to abiotic stress, such as e.g., sulphur deficiency, nitrogen deficiency, or carbon/nitrogen imbalance. In another aspect, the invention thus relates to a transgenic plant cell comprising the expression cassette described above.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales

Abrégé

The invention relates to a strain of fungus Hormonema sp. deposited under the deposit number CECT 13092, comprising the sequences SEQ ID NO: 1 and 2, and to a method for the delignification of lignocellulosic biomass, wherein a strain of fungus deposited under the deposit number CECT 13092 or an enzymatic crude isolated from a strain of fungus deposited under the deposit number CECT 13092 is applied to said lignocellulosic biomass. According to said method, the biomass is biopulped by performing kraft pulping, it is bioblanched by bleaching with hydrogen peroxide, or the delignified biomass is used to produce bioethanol.

Classes IPC  ?

• C12N 1/14 - ChampignonsLeurs milieux de culture
• D21C 3/00 - Réduction en pâte des matières contenant de la cellulose
• D21C 9/16 - Blanchiment avec des per-composés

Abrégé

The invention relates to a micro-organism isolated from breast milk and from the faeces of a nursing infant fed with said breast milk, consisting of a strain of the Bifidobacterium breve species, deposited under the CECT number 8178 in the "Spanish Type Culture Collection" of Valencia, Spain. The invention also relates to the use of the micro-organism as a probiotic material in the development and/or production of milk products and the derivatives thereof. The strain of the present invention has been isolated from breast milk and from faeces of a nursing infant fed with said breast milk.

Classes IPC  ?

• C12N 1/20 - BactériesLeurs milieux de culture
• A23L 1/30 - contenant des additifs (A23L 1/308 a priorité);;
• A23C 9/123 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes ne comportant que des micro-organismes de la famille des lactobactériacéesYoghourt
• A61K 35/74 - Bactéries
• C12R 1/01 - Bactéries ou actinomycètes

Abrégé

The invention relates to the use of proteins of the viral capsid of a virus of the Potyviridae family as a substrate for the immobilisation of enzymes of interest, using a crosslinking agent suitable for joining the proteins of the viral capsid to the enzyme of interest.

Classes IPC  ?

• C12N 11/06 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique attachées au support au moyen d'un agent de pontage

Abrégé

The invention relates to the technological sector of the transport and delivery of molecules into cells, either at cytoplasm or at nucleus or inter-cells (cell to cell transport), using peptides binding proteins from the cell microtubule motor complex, preferably dynein-binding peptides, as carrier/delivery peptides; or functionalized structures, as nanoparticles, linked to said carrier/delivery peptides. This delivery can be useful in many technical fields comprising, among some others: diagnosis, therapy and pharmacology.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides

Abrégé

The invention relates to a dendrimeric peptide construct of formula (I) wherein: T is a T epitope of the FMDV, bound to the lysine core by its N-terminal end, B is a B epitope of the FMDV, W is a linker group, Z is Cys bound to the linker group W through its sulphur atom or Lys bound to the linker group W through its ε amino group, X is absent when B is bound to the α-carboxylic group of Z by its N-terminal end or is an acyl group when B is bound to the α-amino group of Z by its C-terminal end. The invention also refers to the use of said constructs as an immunogen for the prevention of foot-and-mouth disease in an animal.

Classes IPC  ?

• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
• A61K 39/135 - Virus de la fièvre aphteuse

Abrégé

The present invention relates to the use of RNAs that correspond to highly structured domains of the non-coding regions of the genome of the foot-and-mouth virus (FMV) and to the use of sequences that comprise said RNAs for the production of a pharmaceutical composition for the prophylaxis and/or the treatment of diseases caused by interferon-sensitive viruses. The invention also relates to the pharmaceutical composition that comprises the non-coding regions of the invention and that furthermore comprises at least one pharmaceutically acceptable excipient and/or vehicle, and also to the use of said pharmaceutical composition.

Classes IPC  ?

• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The invention relates to the technological sector of the transport and delivery of molecules into cells, either at cytoplasm or at nucleus or inter-cells (cell to cell transport), using peptides binding proteins from the cell microtubule motor complex, preferably dynein-binding peptides, as carrier/delivery peptides; or functionalized structures, as nanoparticles, linked to said carrier/delivery peptides. This delivery can be useful in many technical fields comprising, among some others: diagnosis, therapy and pharmacology.

Classes IPC  ?

• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
• C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• C07K 14/01 - Virus à ADN
• A61P 35/00 - Agents anticancéreux
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires

Abrégé

The present invention relates to liposomes composed of DOPE and/or of a variant of DOPE bearing at least one ligand for targeting dendritic cells, of DOTAP and/or of a variant of DOTAP bearing at least one ligand for targeting dendritic cells and of cardiolipin and/or of a variant of cardiolipin bearing at least one ligand for targeting dendritic cells; and to the use thereof as a genetic material carrier for preparing lipoplexes. The lipoplexes according to the invention are advantageous because of the limited cytotoxicity thereof in vivo; they are therefore of particular interest for gene vaccination; in a form encapsulated in a biodegradable and nonimmunogenic cell such as an alginate gel, they are particularly suitable in particular for oral vaccination of aquatic animals.

Classes IPC  ?

• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament

Abrégé

The invention relates to a method for the delignification of a pulp of cellulose fibres or any other lignocellulosic material (LCM), comprising at least one LCM pre-treatment step including the refining of the LCM, together with the pre-treatment thereof with urea or one of the derivative compounds of same. The invention facilitates the access of both enzymes and chemical reagents into the cellulose fibres, thereby increasing delignification and bleaching, while simultaneously reducing the quantity of reagents and contamination in effluents.

Classes IPC  ?

• D21C 9/10 - Blanchiment

Abrégé

The invention relates to the use of valproic acid or the salts or solvates thereof for the treatment of diseases caused by enveloped viruses, such as, for example, West Nile fever virus or Usutu virus.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The invention relates to the use of flagellins of the genus Marinobacter as vaccination adjuvants. The present invention is based on the use of two recombinant flagellins F and FR of the species Marinobacter algicola (strain DG893T) as vaccination adjuvants capable of developing a specific immune response to peptides or proteins fused to said flagellins, or administered conjointly with the flagellins without fusing thereto. The invention also relates to novel combined vaccination strategies based on said two flagellins of Marinobacter algicola and the flagellin of Salmonella typhimurium.

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques

Abrégé

The present invention describes a transgenic plant resistant to cold and to saline stress based on the use of a new gene, gene RCI5, encoding a monooxygenase enzyme which induces the appearance of TMAO. Moreover, the invention provides a sequence of nucleotides, vectors and cells necessary to carry out the procedure for the obtainment of said transgenic plants. Finally, there is added the use of compositions containing TMAO to improve the tolerance to saline stress of affected plants by means of exogenous application of said solutions onto the plant or seed, for example spraying or injection.

Classes IPC  ?

• A01N 33/24 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux contenant des composés organiques de l'azote comportant des liaisons azote-oxygène un seul atome d'oxygène étant lié à l'atome d'azote
• C12N 15/53 - Oxydoréductases (1)
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• A01H 3/04 - Procédés de modification des phénotypes par traitement au moyen de produits chimiques

Abrégé

The invention relates to an attenuated vaccine against foot-and-mouth disease, with viral variants of the foot-and-mouth disease virus, in which one of the variants includes the deleted genome in the region coding for protease L and another of the variants in the region of the structural proteins. Said variants can complement one another.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 7/08 - Inactivation ou atténuationProduction de parties élémentaires de virus par passages successifs de virus

Abrégé

Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof. The present invention relates to a gene construct that comprises, functionally linked, at least one nucleotide sequence (A) that encodes a polypeptide of SEQ ID No 1 that has a region that recognizes the β chain of the class II DR antigen present on the antigen-presenting cell surface; and a nucleotide sequence (B) that encodes a vaccine antigen of interest. Furthermore, the present invention relates to recombinant vectors that are useful in the expression of the gene construct of the invention, transgenic cells and plants transformed or transfected with said vectors, fusion proteins encoded by the gene construct of the invention and vaccines that comprise said fusion proteins.

Classes IPC  ?

• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• A01H 5/00 - Angiospermes, c.-à-d. plantes à fleurs, caractérisées par leurs parties végétalesAngiospermes caractérisées autrement que par leur taxonomie botanique
• C07K 14/015 - Parvoviridae, p. ex. virus de l'aleucémie féline, parvovirus humain
• C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/12 - Antigènes viraux
• A61K 39/23 - Parvoviridae, p. ex. virus de l'aleucémie féline
• A61P 37/04 - Immunostimulants

Abrégé

The invention relates to a system based on a DNA construction comprising at least the following functionally bound sequences, namely: a nucleic acid sequence (A) containing the nucleotide sequence that codes for a product of interest, and a nucleic acid sequence (B) containing the nucleotide sequence that codes for a tetramerisation domain, such as the tetramerisation domain of protein p53, in which the 3' terminal of nucleic acid sequence A is bound to the 5' terminal of nucleic acid B. The system can be used to produce products of interest, for example recombinant multimeric peptides and proteins which can be used in vaccination, therapy, diagnosis, or industrial enzymes. Plants and insect larvae, transformed with the appropriate vectors such as to express the fused protein or peptide, are used as production systems. The expression of the 2L21 peptide from the canine parvovirus is illustrated in plants and the peptide binding to the dynein of protein p54 from African swine fever virus is illustrated in larvae, in both cases fused respectively to the p53 tetramerisation domain.

Classes IPC  ?

• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C07K 19/00 - Peptides hybrides
• C07K 14/015 - Parvoviridae, p. ex. virus de l'aleucémie féline, parvovirus humain
• C07K 14/185 - Virus du choléra du porc
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

New antiviral peptides interfering the binding of the virus to DLC8 A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycie. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.

Classes IPC  ?

• C07K 14/01 - Virus à ADN

Abrégé

Process which uses a capillary (1) coated with a polymer as a mould, for which purpose the protective layer covering the polymer is partly removed, thereby filling the capillary (1) with a polymerization mixture (3) and closing the ends thereof before then placing the whole combination in a kiln for the time and temperature required to bring about polymerization; said combination is then taken out of the kiln and divided into different fragments (4) which are immersed in a solution (6) with reagents for dissolving the walls of the capillary, thereby obtaining monolithic polymeric fibres (7) for use in solid-phase microextraction, with an ability to retain a compound or family of compounds, a step be performed selectively if a template compound is added to the polymerization mixture.

Classes IPC  ?

• B01J 20/26 - Composés macromoléculaires synthétiques
• B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
• B01J 20/281 - Absorbants ou adsorbants spécialement adaptés pour la chromatographie préparative, analytique ou de recherche
• B01J 20/285 - Absorbants ou adsorbants poreux à base de polymères
• G01N 30/00 - Recherche ou analyse de matériaux par séparation en constituants utilisant l'adsorption, l'absorption ou des phénomènes similaires ou utilisant l'échange d'ions, p. ex. la chromatographie

Abrégé

This construct is one of formula (I), wherein: T is a peptide that contains the SEQ. ID No.1 sequence or a fragment thereof; B is a peptide that contains the SEQ. ID No.2 sequence or a fragment thereof; X is an acyl group bonded to the N-terminal end of B; n is 3 or 4; and L corresponds to a usine nucleus of formula (II), wherein W is a connector group; Z1-Z4 are identical or different from one another and are selected from the group consisting of cysteine and -OH, provided at least three of the groups Z1 to Z4 are cysteine; B being linked to the usine nucleus by its C-terminal end and T being linked to said nucleus by its N-terminal end.

Classes IPC  ?

• C07K 14/09 - Virus de la fièvre aphteuse
• A61K 39/135 - Virus de la fièvre aphteuse
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

In order to prepare unilamellar vesicles of low density lipids, lipids of plant origin are first predissolved; a suitable quantity of lipids, from 4 to 12 mg/ml is mixed with hot pure water and stirred for some 30 minutes, the suspension obtained is held at 50-60°C for one hour and stirred for 2 minutes every 20 minutes. High molecular weight hyalurone is added to the lipid suspension up to a final concentration of 1 mg/ml and the suspension of lipids and hyalurone is emulsified using ultrasound, pumped through a homogenizer valve and immediately passed through a polycarbonate membrane, obtaining a final suspension with 70% of the particles in suspension having a size from 5 to 15 nM, which means that HA and LDL single layer vesicles can be used for cryoconservation and the culture of various mammal cells, especially stem cells.

Classes IPC  ?

• A01N 1/02 - Conservation de parties vivantes
• C12N 5/076 - Cellules du spermeSpermatogonies

Abrégé

Improvements made to the subject matter of patent application No. P200402093, which relates to the immunization of aquatic animals against infection caused by viral, bacterial or parasitic pathogens, by means of the use of DNA-expression systems (vectors) that comprise a potentiating 5’ sequence, a promoter and a nucleic acid sequence that codes for an immunogenic peptide of a pathogen of an aquatic animal. Optionally, the DNA-expression system contains elements of a transposon, which, unlike the vector used in said patent application, increases not only the intensity of expression but also its duration.

Classes IPC  ?

• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques

Abrégé

The invention concerns a method for identifying the genotype in position 171 of the sheep PrP as well as a method for selecting a sheep for reproduction. The invention also concerns kits for implementing said methods. The inventive identifying method includes steps of treating an ovine body fluid sample to be tested containing the PrP with a denaturing and reducing solution, immobilizing, optionally by a ligand, the denatured and reduced PrP on a solid phase, contacting the denatured, reduced and immobilized PrP with at least one detecting antibody, and detecting the possible presence of said at least one detecting antibody, one of the ligand or of said at least one detecting antibody specifically binding to the PrP having a particular allelic state in position 171. The invention is applicable in particular in the medical field, more particularly veterinary and sanitary medicine.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a method of promoting tomato plant growth. The inventive method consists in bringing a suspension of conidia formulated with penicillium oxalicum into contact with the tomato seedlings in the seedling nursery, such that the fungi generated by said conidia enhance the development or growth of the tomato seedlings.

Classes IPC  ?

• A01N 63/04 - Champignons microscopiques; Substances produites par, ou obtenues à partir de champignons microscopiques
• A01N 25/22 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des ingrédients stabilisant les ingrédients actifs